Does lurbinectedin cause blood clotting issues?
Lurbinectedin (Zepzelca), used for metastatic small cell lung cancer, lists thrombocytopenia—a drop in platelet count that can lead to bleeding or bruising—as a common side effect in clinical trials and prescribing information. This occurs in up to 78% of patients, with severe cases (grade 3/4) in 36%.[1][2] It does not directly promote blood clotting (thrombosis) but can indirectly heighten clotting risks through anemia or interactions with supportive treatments like blood transfusions.
How does it impact platelets and bleeding risk?
The drug suppresses bone marrow function, reducing platelets and increasing bleeding risks such as nosebleeds, gum bleeding, or severe hemorrhage. FDA labeling requires platelet monitoring before each dose and dose delays or reductions if counts fall below 100,000 cells/μL.[1] No primary prothrombotic effects are noted, unlike some chemotherapies that trigger clots via inflammation.
What about clotting risks in real-world use?
Post-marketing reports and studies show rare venous thromboembolism (VTE) events, but these link more to underlying cancer or combo therapies (e.g., with doxorubicin) than lurbinectedin alone. A phase 2 trial reported VTE in 5% of patients.[3] Cancer patients already face 4-7x higher clotting risk, so lurbinectedin adds to monitoring needs rather than uniquely causing clots.[4]
Key lab changes patients should watch
Expect drops in hemoglobin (57% incidence), neutrophils (72%), and platelets. Liver enzymes may rise, but coagulation tests (PT/INR, aPTT) rarely change directly from the drug.[1][2] Doctors often pair it with G-CSF for neutrophils and transfusions for platelets.
Drug interactions affecting clotting
Avoid strong CYP3A inhibitors (e.g., ketoconazole), which raise lurbinectedin levels and worsen cytopenias. No major interactions with anticoagulants like warfarin, but platelet effects amplify bleeding risks with them.[1]
[1]: FDA Zepzelca Label
[2]: Drugs.com - Lurbinectedin Side Effects
[3]: Trigo J, et al. Lancet Oncol 2020;21:1457-1466
[4]: NCCN Guidelines for Small Cell Lung Cancer, 2023